BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1413493)

  • 1. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up.
    Bosari S; Lee AK; Viale G; Heatley GJ; Coggi G
    Virchows Arch A Pathol Anat Histopathol; 1992; 421(4):291-5. PubMed ID: 1413493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 protein expression in fine-needle aspirates of breast cancer: an immunocytochemical assay for identifying high-grade ductal carcinomas.
    Colecchia M; Frigo B; Zucchi A; Leopardi O
    Diagn Cytopathol; 1995 Aug; 13(2):128-32; discussion 132-3. PubMed ID: 8542791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
    Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
    Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.
    Kourea HP; Koutras AK; Scopa CD; Marangos MN; Tzoracoeleftherakis E; Koukouras D; Kalofonos HP
    Mol Pathol; 2003 Dec; 56(6):328-35. PubMed ID: 14645695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers.
    Friedrich K; Dimmer V; Haroske G; Lossnitzer A; Kasper M; Theissig F; Kunze KD
    Pathol Res Pract; 1995 Nov; 191(11):1114-21. PubMed ID: 8822113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor.
    Göhring UJ; Scharl A; Heckel C; Ahr A; Crombach G
    Arch Gynecol Obstet; 1995; 256(3):139-46. PubMed ID: 7574906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
    Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
    J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of cytosolic p53 protein in breast cancer.
    Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
    Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
    Allred DC; Clark GM; Elledge R; Fuqua SA; Brown RW; Chamness GC; Osborne CK; McGuire WL
    J Natl Cancer Inst; 1993 Feb; 85(3):200-6. PubMed ID: 8423624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.
    Railo M; Lundin J; Haglund C; von Smitten K; von Boguslawsky K; Nordling S
    Acta Oncol; 1997; 36(4):369-74. PubMed ID: 9247096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
    Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.
    Mirza AN; Mirza NQ; Vlastos G; Singletary SE
    Ann Surg; 2002 Jan; 235(1):10-26. PubMed ID: 11753038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
    González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
    Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases.
    Domagala W; Striker G; Szadowska A; Dukowicz A; Harezga B; Osborn M
    Eur J Cancer; 1994; 30A(10):1527-34. PubMed ID: 7833113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.